NCT03115827View on ClinicalTrials.gov

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

December 21, 2018

Study Completion Date

December 21, 2018

Conditions
Parkinson Disease
Interventions
DRUG

Droxidopa

Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day

DRUG

Carbidopa

Carbidopa 200mg twice a day

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

collaborator

American Academy of Neurology

OTHER

lead

Vanderbilt University Medical Center

OTHER

NCT03115827 - Norepinephrine-targeted Therapy for Action Control in Parkinson Disease | Biotech Hunter | Biotech Hunter